NASDAQ: SLN - Silence Therapeutics plc

Rentabilidade por seis meses: -60.49%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Silence Therapeutics plc

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Silence Therapeutics plc

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.

mais detalhes
The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2020-09-08
ISIN US82686Q1013
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета gbp
Сайт https://www.silence-therapeutics.com
Цена ао 19.27
Alteração de preço por dia: +0.4243% (7.07)
Alteração de preço por semana: +3.2% (6.88)
Alteração de preço por mês: -7.43% (7.67)
Alteração de preço em 3 meses: -61.1% (18.25)
Mudança de preço em seis meses: -60.49% (17.97)
Mudança de preço por ano: -59.12% (17.37)
Mudança de preço em 3 anos: -69.42% (23.22)
Mudança de preço em 5 anos: 0% (7.1)
Mudança de preço em 10 anos: 0% (7.1)
Mudança de preço desde o início do ano: -4.83% (7.46)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 19.51 1
P/BV 29.03 1
P/E 0 0
EV/EBITDA -9.26 0
Total: 3.13

Eficiência

Nome Significado Nota
ROA, % -46.12 0
ROE, % -253.77 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.0057 10
Total: 9.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 10299.59 10
Rentabilidade Ebitda, % 123.97 10
Rentabilidade EPS, % 241.07 10
Total: 8
Mais detalhes

Instituições Volume Compartilhar, %
Lombard Odier Asset Management (USA) Corp 3879173 12.96
Lombard Odier Asset Management (Europe) Ltd 3612877 12.07
Artal Group S.A. 3000000 10.02
Tcg Crossover Management, Llc 2104875 7.03
Deep Track Capital, LP 1951580 6.52
BVF Inc. 1508416 5.04
Aquilo Capital Management, LLC 1043284 3.49
Frazier Life Sciences Management, L.P. 881173 2.94
Vivo Capital, LLC 510204 1.7
Logos Global Management LP 400000 1.34

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
Virtus LifeSci Biotech Clinical Trials ETF 0.73377 63.04 0.33
SPDR Portfolio MSCI Global Stock Market ETF 0 17.99 2.19607



Supervisor Cargo Pagamento Ano de nascimento
Mr. Craig A. Tooman M.B.A. President, CEO & Executive Director 1.49M 1965 (60 anos)
Ms. Rhonda L. Hellums Executive VP, CFO & Secretary 907.23k 1972 (53 ano)
Dr. Steven J. Romano M.D. Executive VP and Chief Research & Development Officer 662.65k 1959 (66 anos)
Dr. Marie Wikstrom Lindholm Ph.D. Chief Scientific Officer N/A
Ms. Gem Gokmen Hopkins Head of IR & Corporate Communications N/A
Dr. Barbara A. Ruskin J.D., Ph.D. Senior VP and Chief Intellectual Property & Innovation Officer N/A 1960 (65 anos)
Dr. Eric Floyd M.B.A., M.S., Ph.D. Senior Vice President of Regulatory Affairs & Quality Assurance N/A 1963 (62 ano)
Mr. J.P. Gabriel Chief Technical Operations Officer N/A
Mr. Curtis Rambaran M.D. Chief Medical Officer N/A
Ms. Gianine Esposito Chief Human Resources Officer

Endereço: United Kingdom, London, 72 Hammersmith Road - abrir no Google Maps, abrir mapas Yandex
Site: https://www.silence-therapeutics.com